Navigation Links
United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
Date:2/15/2011

$9.0 million for the quarter ended December 31, 2010 compared to the same quarter in 2009 reflected primarily: (1) an increase in expenses incurred in connection with our FREEDOM-M and FREEDOM-C2 Phase III clinical trials, which was largely offset by a decrease in expenses related to our inhaled treprostinil program; and (2) an increase of $9.3 million in expenses related to our development of beraprost-MR, which includes $9.0 million in milestone-related expenses. 

Share-based compensation.  The increase in share-based compensation expense of $8.6 million for the quarter ended December 31, 2010 over the same quarter in 2009 reflected: (1) an increase in the fair value of awards granted under our Share Tracking Awards Plan (STAP), principally as a result of the increase in the price of our common stock; (2) an increase in the number of outstanding STAP awards; and (3) increases in both the number of STAP awards vested and the time that unvested STAP awards had accrued toward vesting as of December 31, 2010.

Other.  Other research and development expenses increased $3.6 million during the quarter ended December 31, 2010 compared to the same quarter in 2009 reflected primarily an increase in personnel, depreciation and overhead costs supporting our research mainly because 2010 was the first full year of operations of our new facilities in North Carolina and Maryland. Research and development expenses for our individual disease platforms include only direct labor and related direct costs.

The table below summarizes selling, general and administrative expense by major categories (in thousands):Three Months EndedDecember 31,Year EndedDecember 31,2010200920102009CategoryGeneral and administrative

$

28,302$

28,894$

83,077$

68,606Sales and marketing

14,14711,86049,33243,593Share-based compensation

32,54915,82367
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
2. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
3. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
4. United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008
5. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
6. Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States
7. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
8. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
9. United Therapeutics Reports Third Quarter 2008 Financial Results
10. Lilly Contributes $11.1 Million to United Way Annual Campaign
11. First United Kingdom Patients Treated With Percutaneous MitraClip(R) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Research and Markets ... the "Analysis of the Global Flow Cytometry ... Globally, flow cytometry remains a popular tool ... and stem cells. But the market is witnessing ... demand from underdeveloped nations to quantitate CD4 cell ...
(Date:7/28/2015)... 2015  Kerastem Technologies announce that the Company has ... Center For Biologics Evaluation and Research (CBER) Office of ... trial investigating the safety and feasibility of the Company,s ... pattern baldness (androgenic alopecia). The phase II ... work in Europe and ...
(Date:7/28/2015)... N.C., July 28, 2015  United Therapeutics Corporation (NASDAQ: ... for the second quarter ended June 30, 2015. ... compared to the second quarter of 2014 when ... Ph.D., United Therapeutics, President and Co-Chief Executive Officer. ... an increase in the number of patients being ...
(Date:7/27/2015)... , July 27, 2015 /PRNewswire/ - Quest PharmaTech ... company developing and commercializing products for the treatment of ... Quest announces that it has closed a $1,000,000 unit ... placement of 16,666,667 units of the Company at a ... of one common share and one common share purchase ...
Breaking Biology Technology:Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11Quest PharmaTech Closes $1,000,000 Private Placement 2
... Ohio and LOD, Israel, November 3 Simbionix,USA ... hands-on,curriculum for training medical professionals, today announced that ... US Marketing Director on,November 10th, 2008. Gary Zamler, ... Simbionix has enjoyed double digit revenue growth in,both ...
... Telomolecular CEO, Matthew Sarad, clarifies the scope and terms of his ... ... (PRWEB) November 3, 2008 -- Telomolecular, a Rancho Cordova, California Corporation, ... therapeutics to treat diseases of aging and cancer, particularly diseases related ...
... compound in sufficient and rapidly produced yields, potentially ... could boost semiconductor capabilities for large-area applications. , ... the first heterometallic gallium-indium hydroxide nanocluster was the ... of nitrosobenzene. , The substitute was identified during ...
Cached Biology Technology:William E. Lewandowski to Lead Simbionix US Marketing Team in Simbionix's Strategic Expansion in the US Market 2Former Telomolecular CEO Clarifies SEC Settlement 2Former Telomolecular CEO Clarifies SEC Settlement 3New nanocluster to boost thin films for semiconductors 2
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/7/2015)... -- Research and Markets ( ... "Capacitive Fingerprint Sensors Patent Landscape" report ... fingerprint sensing technology is the most reliable and ... developed. This patent landscape focuses on fingerprint sensors ... of capacitive fingerprint sensors is closely linked to ...
(Date:7/2/2015)... 2015 Research and Markets( ... "Next Generation Biometrics Market by Application, Technology, Function & ... their offering. The next generation biometrics market ... a CAGR of 17.9% between 2015 and 2020 ... the market. Safran SA ( France ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... HOLE, MATiny, toxic protein particles severely disrupt neurotransmission and ... separate studies by Marine Biological Laboratory (MBL) researchers have ... beta, which has long been known to accumulate and ... "These small particles that haven,t aggregated into plaquesthese ...
... A University of Florida scientist whose interest in ... molecular building blocks that shape appendages ranging from feet ... Early Career Scientist today (Thursday, March 26), a distinction ... Martin Cohn, a developmental biologist and a member ...
... A material developed at the Hebrew University of ... following surgery has led to approval by the U.S. ... use in pediatric cardiac surgery patients. The ... of novel, tailor-made, biodegradable polymers for the prevention of ...
Cached Biology News:Tiny but toxic: MBL researchers discover a mechanism of neurodegeneration in Alzheimer's disease 2UF scientist tapped by Howard Hughes Medical Institute to pursue 'best ideas' 2UF scientist tapped by Howard Hughes Medical Institute to pursue 'best ideas' 3Hebrew University professor's work leads to FDA approval for product 2
Applications: (+) Immunocytochemistry and immunohistochemistry...
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
Request Info...
SAIVI Alexa Fluor 680 injectable contrast agent *bovine serum albumin*...
Biology Products: